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Introduction: Cachexia is a syndrome characterized by body weight loss, muscle wasting, 
and metabolic abnormalities, that frequently complicates the management of people 
affected by chronic diseases. No effective therapy is actually available, although several 
drugs are under clinical evaluation. Altered energy metabolism markedly contributes to the 
pathogenesis of cachexia; it can be improved by exercise, able to both induce anabolism 
and inhibit catabolism. 
Areas covered in this review: This review will focus on exercise mimetics and on their 
potential inclusion in combined protocols to treat cachexia, with particular reference to the 
cancer-associated one.    
Expert opinion: Despite exercise improves muscle phenotype, most patients retain 
sedentary habits quite difficult to disrupt. Moreover, they frequently present with chronic 
fatigue and co-morbidities that reduce exercise tolerance. For these reasons drugs 
mimicking exercise could be beneficial also in the absence of patient compliance to the 
practice of physical activity. Different exercise mimetics are now available and, yet some of 
them may exert serious side-effects, investigating their effectiveness on muscle phenotype 






1. Introduction  
Cachexia is a multi-organ syndrome that frequently occurs in chronic pathologies 
such as autoimmune or neurodegenerative diseases, sepsis, diabetes and cancer. The 
etiopathogenesis of cachexia is multifactorial, including reduced caloric intake, altered 
energy and protein metabolism, enhanced lipolysis, systemic inflammation, perturbations 
of the hormonal homeostasis. Among the different features that characterize the onset and 
progression of cachexia, body weight loss and inflammation are the most relevant (1). 
 In cachexia, both skeletal muscle mass and function are markedly reduced. Muscle 
nitrogen balance is regulated by a complex network of factors, such as humoral mediators, 
nutrient and energy availability, or contractile activity, all of which concur to unbalance 
protein turnover rates, favoring degradation. Ca2+-dependent, ATP-ubiquitin-dependent  
and autophagic lysosomal pathways have all been shown to contribute to muscle protein 
wasting (2). Since the discovery and characterization of  different muscle-specific ubiquitin 
ligases(3), attempts have been made to antagonize muscle depletion by targeting these 
enzymes. The results, however, do not allow to validate ubiquitin ligases as therapeutic 
targets for muscle wasting. Not only, specific systemic inhibition of  the different proteolytic 
pathways does not appear as an effective strategy to contrast the progression of cachexia. 
This has been shown for proteasome inhibitors such as bortezomib(4)(5), while suppression 
of autophagy may even reveal detrimental(6)(7)(8). The possibility that muscle-specific 
inhibition of proteolysis might prove effective remains an open question, however. 
 In various forns of cachexia muscle protein wasting is associated with an unbalance 
between pro- and anti-inflammatory cytokines, due to chronic inflammation. For example, 
circulating levels of Tumor Necrosis Factor (TNF)α and TNF soluble receptors are 
increased in patients affected by cancer, chronic renal or heart failure(9)(10)(11), while mice 
lacking the anti-inflammatory IL-10 display muscle depletion and weakness(12). Pro-
inflammatory cytokines, in particular, play a pivotal role in modulating muscle protein 
turnover. Systemic inflammation is associated with enhanced rates of protein degradation, 
that can be paralleled or not by  decreased protein synthesis. Cytokine-induced activation 
of the transcription factors Nuclear Factor (NF)-κB and Signal Transducer and Activator of 
Transcription (STAT)3 results in muscle atrophy(13)(14). Several studies report that 
anabolism can also be affected by pro-inflammatory cytokines. As an example, TNFα 
down-regulates anabolic signaling pathways such as those activated by insulin and 
Insulin-like Growth Factor (IGF)-1(15). Particularly relevant to muscle mass homeostasis 
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are the insulin receptor substrate (IRS)-1/PI3K/Akt axis(16) and the signaling pathways 
dependent on myostatin(15)(17) or on bone morphogenetic proteins(18), all of which are 
subject to cytokine-mediated modulations. 
 
2. Therapeutic approaches to cancer cachexia 
 Cachexia develops in a large proportion of cancer patients, being estimated to 
account for about 20% of cancer-related deaths(1). Its occurrence markedly complicates 
patient management, negatively impinging on the tolerance and response to antineoplastic 
treatments, and on the quality of life as well. Reverting overt cachexia, however, definitely 
is not an easy task, and the most likely scenario is to develop strategies aimed at delaying 
its onset. To achieve this goal, early stages of cachexia must be identified. Along this line, 
Fearon and collaborators(15) proposed a classification that defines three progressive 
stages (pre-cachexia, cachexia, and refractory cachexia), aimed to help clinicians to start 
the few available treatments as soon as possible. 
 Studies performed on experimental models have provided the basis for potential 
treatments of human cachexia, some of which are in phase I or II clinical trials. Provided 
the multifactorial nature of this syndrome, the rationale of such approaches ranges from 
nutritional support to the inhibition of specific molecular pathways. 
 The early institution of a personalized nutritional counseling is recommended to 
improve patient nutritional status, treatment tolerance and clinical outcome. Indeed, the 
maintenance of patient body weight by nutritional interventions allows the completion of 
chemotherapy, frequently interrupted because of severe side effects(19). In this regard, 
several agents have been tested to treat anorexia and increase appetite, such as 
corticosteroids, progestins (megestrol acetate), cannabinoids, ghrelin and its analogues 
(anamorelin), branched-chain amino acids(20).  
 Since systemic inflammation frequently occurs in cancer patients (see above), 
several anti-inflammatory drugs have been tested in experimental cachexia: steroids and 
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), anti-cytokine agents (pentoxifylline, 
thalidomide), anti-cytokine (IL-6, TNF) antibodies, ω-3 polyunsaturated fatty acids. Most of 
these agents, however, have not been validated for the clinical use, although some of 
them (NSAIDs, ω-3 polyunsaturated fatty acids) reached the clinical evaluation(20). 
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 The metabolic alterations underlying cancer cachexia point towards enhanced 
catabolism and reduced anabolism. Accordingly, anabolic and/or anticatabolic strategies 
have been adopted to modulate these processes and attempts have been made to 
modulate the Growth Hormone (GH)/insulin/IGF-1 axis, the androgen-dependent signaling 
(anabolic-androgenic steroids, selective androgen receptor modulators), or the availability 
of amino acids and their metabolites (branched-chain amino acids, β-hydroxy-β-
methylbutyrate, glutamine)(20).  
 Finally, based on the mechanisms contributing to cancer-induced cachexia, some 
experimental drugs are currently under investigation, including anti-myostatin agents, β-
adrenergic agonists, mitogen-activated protein kinase kinase (MEK), and extracellular 
signal regulated protein kinase (ERK) inhibitors, Interleukin (IL)-15. Although encouraging, 
in some cases at least, at the moment the results do not favor the possibility of their rapid 
translation into the clinical practice. 
 
3. Novel aspects in the pathogenesis of cachexia: myogenesis and mitochondria 
 In the last few years two aspects have added complexity to the pathogenesis of 
cachexia: 1) the reduced myogenic potential; 2) the altered mitochondrial structure and 
function. 
 
3.1 Impaired myogenesis  
Myogenesis allows the development of skeletal muscle during the embryonal life. In 
the adulthood it drives the repair of injured muscles and the maintenance of physiological 
muscle cell renewal. After damage, myofiber degeneration is compensated by the 
regeneration of new fibers afforded by proliferation and subsequent fusion of resident 
myogenic precursors, mainly satellite cells (SCs)(21). Impaired myogenesis has been 
associated with pathological muscle wasting. The levels of Pax7, a marker of SC 
proliferation, and those of myogenin, an indicator of ongoing differentiation, respectively 
increase and decrease, respectively, in the muscle of mice bearing the colon 26 carcinoma 
(C26) as well as in cancer patients, suggesting that myogenic precursors accumulate in 
the skeletal muscle of tumor hosts(22)(23)(24). This process appears to depend on the 
maintenance of elevated Pax7 expression, apparently related to activation of the 
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transcription factor NF-κB(23). Impaired myogenesis is associated with enhanced signaling 
through the stress kinase ERK, which is known to maintain cells in an undifferentiated 
state(22). Indeed, treatment of C26-bearing mice with PD98059, a MEK inhibitor able to 
block ERK activation, restores the physiological levels of both Pax7 and myogenin 
expression(22). In agreement with these results, muscle gain has been observed in 
cholangiocarcinoma patients assuming selumetinib, another MEK inhibitor(25). Finally, the 
administration of the multikinase inhibitor sorafenib has been shown to improve both 
muscle wasting and physical activity in mice hosting the C26 or the Lewis Lung Carcinoma 
(LLC). Such effects are associated with modulation of both STAT3 and ERK activity in the 
muscle, leading to reduced expression of Pax7 and atrogin-1(26). Further investigations in 
this direction are warranted to clarify if ERK can be a suitable therapeutic target in cancer 
cachexia.  
 
3.2 Impaired mitochondrial function  
 Since mitochondria are the main source of the energy required for contraction, 
alterations in their homeostasis markedly affect muscle function. While the concept of 
energy wasting is not new in the literature on cancer cachexia(1), the underlying 
mechanisms became a hot topic just recently. Ultrastructural alterations have been 
reported in muscle mitochondria of animals bearing the C26(27), the LLC (Pin, Busquets et 
al., under revision) or the Yoshida Ascited Hepatoma (AH)-130 tumors(28). Mitochondrial 
uncoupling occurs and oxidative capacity  decreases in the muscle of tumor hosts(29)(30), 
consistently with the occurrence of a shift from oxidative to glycolytic fibers (Pin, Busquets 
et al., under revision). Humoral mediators contribute to mitochondrial impairment. As an 
example, TNFα-induced activation of NF-κB reduces muscle oxidative capacity and 
negatively regulates the expression of molecules relevant to mitochondrial biogenesis(29). 
C2C12 myotubes cultured in the presence of LLC cell conditioned medium show 
alterations of the electronic flow in the electron transport chain(31) and finally, muscle 
wasting in the ApcMin/+ mice, an experimental model of IL-6 driven cancer cachexia, is 
associated with altered expression of proteins regulating mitochondrial biogenesis and 
fusion(32). 
 A relation between mitochondria dynamics (balance between fission and fusion 
processes) and protein breakdown in the skeletal muscle has been previously 
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described(33)(34). Mitochondrial dysfunction, leading to oxidative and energy stress, would 
lead to hyperactivation of muscle proteolytic systems through adenosine monophosphate-
activated protein kinase (AMPK)- and Forkhead transcription factor (Fox)O-dependent 
pathways(33), ultimately resulting in muscle wasting. 
 
4. Importance of exercise in the management of cachexia 
 Most of the ongoing clinical trials are based on the use of nutritional and 
pharmacological interventions aimed at preventing the loss of body weight and muscle 
mass. However, muscle 'quality' is as important as  muscle 'quantity'. Both aspects could 
be targeted by exercise training. Indeed, stimulating the increase of muscle mass and 
strength, it might improve cancer-induced wasting by both activating anabolic pathways 
and down-regulating the activity of pro-inflammatory cytokines(35).  
 Two different exercise modalities can be chosen: 1) resistance exercise, that 
causes a mechanical strain on the muscle resulting in different adaptations, among which 
hypertrophy, that occurs primarily through the accretion of contractile proteins, increases 
the capacity to generate force; and 2) endurance exercise, that generally leads to 
metabolic adaptations such as increased number of mitochondria, fiber-type shift to an 
oxidative profile and increased capillary density, with little changes in the skeletal muscle 
mass(36).  
Endurance exercise increases the expression of the peroxisome proliferator-
activated receptor (PPAR)-γ coactivator-1α (PGC-1α), a transcriptional co-regulator that 
binds to several transcription factors to promote mitochondrial biogenesis and oxidative 
metabolism(37). Moreover, exercise also induces the expression of genes involved in 
mitophagy(38), a process that accounts for the clearance of damaged mitochondria. 
Consistently, PGC-1α  has been recently shown to regulate mitophagy in the skeletal 
muscle(39), while the reduced mitochondrial content reported in ApcMin/+ cachectic mice is 
associated with down-regulation of PGC-1α and mitochondrial fusion proteins(32). Finally, 
both resistance and endurance exercise appear to stimulate the proliferation of SCs, 
promoting myogenesis (see above)(40)(41).  
Taking into account that at least some of the metabolic changes occurring in the 
skeletal muscle of cancer patients (alterations of mitochondrial structure, reduced ATP 
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synthesis, shift from oxidative to glycolytic metabolism, impaired myogenesis)(1)(42) can be 
rescued by physical training, a combination of endurance and resistance exercise would 
probably be the right choice to improve cachexia.  
 
5. Drugs mimicking exercise 
 At present three main classes of drugs mimicking the effects of aerobic/endurance 
exercise have been described: agonists of PPARδ or of AMPK and molecules able to 
activate silent-information-regulator-two-protein (SIRT)1. In addition, hyperexpression of 
PGC-1α could be an effective strategy, too.  
 PPARδ, the most abundant PPAR in the skeletal muscle, is involved in the 
regulation of lipid metabolism, mitochondrial function and fiber-type determination. Its 
expression in the skeletal muscle is induced by exercise. As a consequence of its 
activation the energy source is switched from glucose to fatty acids and myofiber 
phenotype converted from fast (glycolytic) to slow (oxidative) twitch. Muscles in mice 
overexpressing PPARδ are characterized by increased proportion of oxidative fibers, 
enhanced activity of enzymes involved in the oxidation/phosphorylation reactions, and 
increased mitochondrial biogenesis and uncoupling proteins(43).  Moreover, constitutive 
hyperactivation of PPARδ results in increased exercise capacity and in protection against 
diet-induced obesity or type 2 diabetes(44). By contrast, lack of PPARδ leads to an opposite 
muscle phenotype, characterized by slow-to-fast myofiber conversion and down-regulation 
of gene products involved in fatty acid oxidation(45). 
 Among the various PPARδ agonists presently available, the most widely studied is 
GW501516, which has been shown to activate PPARδ in an exercise-like manner, 
although not reproducing the increased mitochondrial gene expression and function or the 
switch of fiber type(46)(47). Increased fat versus carbohydrate oxidation rate, up-regulation of 
mitochondrial biogenesis and increased expression of genes encoding contractile proteins 
characteristic of type I myofibers can be observed in mice after few days of synthetic 
PPARδ agonist administration to mice(44). Moreover, both angiogenesis and biogenesis of 
mitochondria are induced in mice 24 h after GW0742 administration, while a fiber type 
switch is evident after 48h(48). Finally, myocyte cultures exposed to PPARδ agonists show 
increased glucose and fatty acid metabolism, with enhanced expression and activation of 
AMPK and p38(48).  
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 The potential of small molecule PPARδ agonists to treat various pathological 
conditions is highlighted by several studies. As an example, GW501516 improves 
experimental atherosclerosis in apoE-/- mice(49), while its administration to obese mice 
reduces weight gain and increases both resting energy expenditure and peripheral insulin 
sensitivity(50). Just few studies investigate PPARδ agonist effects in humans. The results 
suggest that these drugs could reduce obesity, insulin resistance and hyperlipidemia. 
Indeed, treatment with GW501516 results in improved circulating apolipoproteins, LDL and 
HDL cholesterol and hepatosteatosis(51). Finally, administration of MBX-8025 to 
moderately obese subjects improves circulating lipid and cholesterol profiles(52). However, 
very few data are available to define if PPARδ agonists can also affect muscle phenotype. 
GW501516 treatment improves muscle dystrophy by down-regulating inflammation-
dependent pathways(53). The same drug attenuates metabolic abnormalities and improves 
muscle phenotype in experimental models of cardiovascular disease(48). A specific class of 
PPAR agonists, namely glitazones, known for their insulin sensitizing action in the skeletal 
muscle, appear promising to treat muscle atrophy, but their clinical use is controversial. 
Data obtained on a genetic model of diabetes, the db/db mice, show that rosiglitazone 
improves insulin resistance and Akt-dependent signaling pathway, while it inhibits both 
muscle proteasome and caspase 3 activities(54). In addition, a transient muscle-sparing 
effect associated with normalization of PPARδ expression has been reported in C26-
bearing mice treated with rosiglitazone(55)(56). Despite the above described positive effects, 
however, elderly obese patients practicing resistance training and assuming pioglitazone 
show both visceral fat and muscle depletion(57), while contradictory results have been 
reported also for other PPARδ agonists. Treatment of L6 myotubes with the GW0742 
increases protein degradation and reduces myotube size, and rats administered the 
PPARδ inhibitor GSK0660 are resistant to glucocorticoid or sepsis-induced muscle protein 
breakdown(58). These findings are in line with previous data showing that PPARδ 
expression is induced in the skeletal muscle of tumor-bearing rats(59). A final consideration 
is that glitazones show several severe side effects, including cardiovascular and hepatic 
adverse events and increased risk of cancer development(60). For these reasons, 
rosiglitazone has been withdrawn from the european market by EMA, while strict criteria 
for prescriptions and additional warning labeling are required by FDA(61). 
 AMPK activation results in modulations of the metabolic balance aimed to spare 
energy, mainly achieved by stimulating catabolism and inhibiting anabolism. For example, 
AMPK activation induces the expression of muscle-specific ubiquitin ligases and 
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stimulates autophagy(62)(63). Genetic AMPK inactivation in the muscle results in reduced 
mitochondrial mass, loss of type I fibers and reduced lipid metabolism. However, besides 
the pro-catabolic action of AMPK, the enhancement of its activity leads to increased 
oxidative metabolism and exercise efficiency(64). In this regard, AMPK activation should be 
pursued in pathological states characterized by energy deficit, despite the concomitant 
occurrence of hypercatabolism. 
 The activation of AMPK can be achieved by drugs such as 5-aminoimidazole- 4-
carboxyamide ribonucleoside (AICAR), metformin, β-guanidinoproprionic acid (β-GPA), 
resveratrol, quercetin, and salicylate(48). Increased fatty acid oxidation and oxygen 
consumption, IIb-to-IIx myosin isoform shift, enhanced aerobic capacity and running 
endurance have been reported after AICAR administration to experimental animals(46). 
AICAR-induced AMPK activation improves muscle phenotype in dystrophic mdx mice by 
activating autophagy(53). The same drug reverts angiotensin II-induced muscle wasting, 
down-regulating the induction of the muscle-specific ubiquitin ligases and improving PGC-
1α expression(65). Chronic administration of β-GPA to experimental animals induces a fast-
to-slow myofiber shift, increases PGC-1α expression and reduces muscle content of 
Receptor-interacting protein (RIP)140, a repressor of the oxidative phenotype (reviewed 
in(48).  
 As for metformin, few studies investigate its effects on muscle atrophy, both in 
humans and in experimental animals. Severely burned patients treated with metformin 
show reduced endogenous glucose production and increased glucose clearance and 
oxidation, with decreased glycemia. In parallel muscle wasting is improved, due to 
increased protein synthesis rather than to reduced breakdown(66). Metformin appears to 
improve aging-related sarcopenia(67) and has been proposed to treat cancer-induced 
muscle wasting(68). 
 AMPK can also be activated by resveratrol, since many effects exerted on the 
muscle by this drug are attenuated by AMPK inhibition. Consistently, the increased 
mitochondrial biogenesis and endurance performance induced by resveratrol in wild type 
mice cannot be observed when the drug is administered to  AMPKα1 or -α2 deficient 
mice(69). Similarly, muscle wasting and reduced AMPK activation in IL-10 deficient mice 
can be improved by grape seed extract(70). Finally, resveratrol administration to obese men 
activates AMPK and increases PGC-1α and SIRT1 protein levels, improving circulating 
lipid profile and inflammation(71).  
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   Mammalian sirtuins (SIRT1–7) are a class of deacetylases involved in several 
processes such as metabolic regulation, cell death, autophagy, DNA repair and circadian 
rhythm. In addition, SIRTs appear crucial in lifespan regulation in lower eukaryotes, while 
not in healthy mice(72). SIRT deregulation is involved in aging as well as in chronic 
pathologies such as obesity and cancer(73).  
 SIRT1 is the most extensively studied. It is involved in the modulation of various 
epigenetic mechanisms  and also behaves as a critical regulator of energy homeostasis.  
SIRT1 positively modulates several processes such as cell survival, autophagic protein 
degradation, insulin production, regulation of mitochondrial mass, lipid metabolism and 
glucose homeostasis(73). Consistent with its role as energy regulator, SIRT1 expression is 
induced in response to caloric restriction(73), and can be activated in the skeletal muscle by 
AMPK, linking a critical energy sensor to a regulator of aerobic capacity(74). 
 Mice genetically deficient of SIRT1 show inflammation and metabolic defects(75), 
while SIRT1 hyperexpression improves high fat diet-induced metabolic alterations(76). 
Recent data show that muscle-specific SIRT1 overexpression causes a fast-to-slow fiber 
type transition. Such modification is paralleled by reduced gastrocnemius weight, which is 
consistent with the lower cross sectional area of oxidative compared to glycolytic fibers. 
However, transgenic animals are protected, partially at least, from fasting or denervation-
induced atrogene hyperexpression(77). Finally, muscle phenotype in mdx/SIRT1 double 
transgenic mice is improved(78). 
 Both natural and synthetic SIRT1 activators are available. Among the former, 
polyphenols, such as resveratrol, are the most studied. Resveratrol administration to mice 
increases increased muscle mitochondrial biogenesis and oxidative metabolism, resulting 
in enhanced exercise capacity and in protection against obesity and type 2 diabetes(79). 
Resveratrol improves the lifespan of mice maintained on high fat diet(80) and is also 
beneficial in obese humans (see above). Part of the effects exerted by resveratrol derive 
from SIRT1-dependent modulations of PGC-1α acetylation state, and are recapitulated by 
selective SIRT1 activators(81). 
 Synthetic selective SIRT1 activators such as SRT2104 appear well tolerated in 
healthy adults and in elderly people(82)(83). SRT2104 administration to healthy volunteers 
improves plasma lipid profile and insulin sensitivity(82)(84). At present no studies address the 
effectiveness of synthetic SIRT1 activators on muscle mass and function in humans. Such 
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aspect has been recently investigated in an experimental study where short-term 
treatment with SRT2104 has been shown to attenuate muscle mass depletion induced by 
inactivity or fasting(85). The protection exerted by SRT2104 on inactivity-induced muscle 
atrophy is associated with increased PGC-1α levels(85), consistent with previous 
observations showing that PGC-1α overexpression is able to protect against muscle 
atrophy induced by denervation or fasting(86).  
 PGC-1α is currently considered one of the major regulators of exercise-induced 
phenotypic adaptation in the skeletal muscle. It modulates mitochondrial biogenesis and its 
hyperexpression leads to increased mitochondrial mass and enhanced oxidative 
metabolism(87).  
 Both transcriptional and post-translational mechanisms contribute to regulate PGC-
1α activity. As an example, endurance exercise leads to PGC-1α deacetylation, up-
regulating the expression of several target genes. Exercise-induced activation of PGC-1α 
may also be influenced by different signaling pathways such as those dependent on 
Mitogen Activated Protein Kinases (MAPKs), oxidative stress, AMPK, SIRT1(87). 
 In the skeletal muscle PGC-1α participates in fiber-type specification, promoting a 
fast-to-slow transition. When specifically overexpressed in the muscle, it leads to a 
markedly oxidative phenotype characterized by high respiratory capacity and increased 
resistance to fatigue that result in improved exercise performance, without affecting 
muscle mass. Such phenotype closely resembles the one induced by aerobic training. By 
contrast, lack of PGC-1α results in decreased exercise performance and  oxidative 
metabolism, paralleled by a slow-to-fast fiber type transition(87). Evidence has been 
provided of a link between PGC-1α and the TNF-like weak inducer of apoptosis (TWEAK)-
Fibroblast growth factor inducible (Fn)14 signaling pathway(88), known to be involved in 
muscle atrophy(89). Indeed, muscle-specific PGC-1α overexpression has been shown 
to inhibit TWEAK-induced expression of atrogenes and to prevent the inducible expression 
of TWEAK receptor Fn14 in denervated muscle(88). Finally, recent results obtained in our 
laboratory show that PGC-1α overexpression improves muscle wasting in tumor-bearing 
mice (Pin, Busquets et al., under revision). These results are consistent with those 
reported by Ruas and coworkers(90), showing that transgenic mice overexpressing the 
PGC-1α4 isoform, characterized by muscle hypertrophy, are more resistant than wild-type 





 In the last decades several mechanisms underlying muscle wasting in cachexia 
have been unraveled, however further research is required, with particular reference to the 
need to confirm in humans data arising from animal models. The reduction of physical 
activity that generally occurs in cancer patients likely significantly contributes to the 
pathogenesis of muscle wasting in cachexia. For this reason, exercise training is regarded 
as a promising intervention that can attenuate cancer-induced muscle wasting. However, 
since exercise capability can be impaired in cancer patients, drugs able to mimick exercise 
effects would be welcome. In this regard, PPARδ or AMPK agonists as well as SIRT1 
activators have been proposed as potentially useful drugs (Table 1). The results actually 
available are encouraging but still at the pre-clinical level. Further studies are thus 
warranted to extend the experimental observations and to translate them to the clinical 
practice. 
 
7. Expert opinion 
 Cancer cachexia originates from a complex network of profound metabolic 
alterations that reflects the action of inflammatory mediators, of energy deficit and of 
hypercatabolic stimuli. At the molecular level at least, such perturbations may occur at very 
early disease stages, well before any evidence of general wasting.  
 Tumor eradication obviously is the only radical approach to deal with cachexia. 
However, not only this goal is totally beyond reach, but cachexia compromises its 
feasibility. Therefore, reliable therapeutic strategies aimed at interfering with the onset 
and/or progression of cachexia need to be pursued and timely implemented in patients. On 
the basis of results obtained in experimental studies, several drugs are now under 
evaluation in clinical trials to test their effectiveness in preventing/delaying cachexia in 
cancer patients. The rationale underlying such trials is quite variable. In general, however, 
it is important to realize that monotherapies are hardly adequate to deal with cachexia and 
this view seems to gain a growing consensus. Rather, the most suitable approach should 
likely be a multidirectional one, selectively tailored, whenever possible, on a panel of the 
manifold and variable (e.g., inflammatory cytokines) pathogenic factors involved. 
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 In the last years the knowledge about the mechanisms underlying cachexia has 
expanded considerably, also taking into consideration impaired myogenesis and the 
occurrence of energy deficit, paving the way to new potential therapeutic targets. Few 
attempts to improve cachexia by impinging, directly or indirectly, on myogenesis have 
been reported so far (see above). While the results appear encouraging, further studies 
are needed to clarify this issue. 
 The occurrence of energy dysmetabolism in cachexia is long recognized, however 
the research on the underlying mechanisms and the definition of useful therapeutic 
strategies is at the very beginning. In the last years, alterations in mitochondrial structure 
and function have been reported in the skeletal muscle of cancer hosts. Being 
mitochondria the main source of energy used by the muscle for contractile activity, their 
dysfunction would result in oxidative and energy stress, ultimately contributing to muscle 
wasting. Exercise has proven to be very effective to improve muscle phenotype by 
impinging on both anabolic and catabolic (pro-inflammatory) pathways.   
 Despite the potentially favorable perspectives reported above, to disrupt the 
sedentary habits shared by most patients is not an easy task. In addition, chronic fatigue 
and co-morbidities frequently occurring in cancer patients, such as anemia and cardiac 
dysfunctions, are limiting factors for practicing physical activity, and can eventually lead to 
exercise intolerance. Consistently, muscle wasting is not prevented by exercise in mice 
bearing the C26 tumor (Pin, Busquets et al., under revision), in which cachexia is 
associated with anemia and cardiac alterations(91), while excessive endurance exercise is 
associated with increased mitochondrial fission in the absence of mitophagy induction(92). 
For these reasons, the availability of drugs that mimic the effects of exercise action would 
be desirable in order to maintain the beneficial effects of exercise avoiding the negative 
aspects represented by potential muscle injury and by the need of a 'permissive' energy 
metabolism, frequently lacking in cancer patients, especially in advanced disease stages 
(Figure 1). 
  The strength of the research on drugs mimicking exercise is to clarify if they can 
effectively become part of a tailored therapeutic protocol aimed at preventing/delaying 
cachexia. This would allow the maintenance of cancer patients in the pre-cachexia stage 
as long as possible, markedly improving the possibility to complete the scheduled 
antineoplastic treatment, achieving the most possible effectiveness. However, since in 
most cases the data available on drugs mimicking exercise are at the pre-clinical level, 
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studies aimed at validating the results also at the clinical level are warranted. This is not an 
easy task, however, since such studies would be more complicated, in terms of both 
invasiveness of the approach and ethical issues, than prospective clinical investigations 
based on anthropometric and/or biological fluid-derived data. 
 Finally, a note of care must be posed, since many exercise mimetics, in particular 
those able to induce PPARδ (glitazones, metformin), may produce dangerous side-effects 
such as worsening the cardiovascular function or increasing the oncogenic risk. In this 
regard, studies should concentrate on those drugs able to improve energy metabolism, 
acting on mitochondrial turnover and oxidative metabolism, being well tolerated at the 
same time.  
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PPARδ AGONISTS   
GW501516 pre-clinical 44, 46-48, 53 
GW0742 pre-clinical 48 
glitazones pre-clinical 54-56 
AMPK ACTIVATORS   
AICAR pre-clinical 46, 53, 65 
β-GPA pre-clinical 48 
metformin clinical 66-68 
resveratrol pre-clinical 69, 70 
SIRT1 ACTIVATORS   
resveratrol pre-clinical 79, 81 
SRT2104 pre-clinical 85, 86 
Drugs currently under investigation for their use as exercise  
mimetics are listed. References reporting effects on target  




Figure 1. Different classes of molecules are able to mimic the effects of 
aerobic/endurance exercise. Both host cells and the tumor secrete humoral factors and 
produce metabolic changes which modify skeletal muscle gene expression and cause cell 
damage. These alterations lead to the hyperactivation of protein degradation, affect  
myogenesis and impair mitochondrial function, ultimately leading to muscle wasting. 
Exercise mimetics (green squares) act on exercise-responsive factors (AMPK, PPARδ, 
PGC-1α, SIRT1), improving the energy deficit by restoring mitochondrial biogenesis, 
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